NCT02876302 2026-02-04
Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT02928978 2025-02-14
TBCRC042
Baylor Breast Care Center
Phase 2 Active not recruiting
NCT01594216 2024-06-12
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02120417 2018-02-13
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Incyte Corporation
Phase 2 Terminated
NCT01562873 2017-02-23
Ruxolitinib in Patients With Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated